TCT 792: First-in-human experience with a novel self-expandable coronary sinus reducer for treating symptomatic epicardial and microvascular ischemic heart disease

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Neovasc; VahatiCor</li></ul>